Answers are grounded in this paper and cite their sources.
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease worldwide and is characterized by excessive hepatic fat accumulation that can progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Currently, resmetirom is the only FDA‐approved drug for NASH, but its clinical benefits are limited to a subset of patients, and no approved therapies exist for non‐NASH NAFLD. Therefore, developing novel agents targeting the full NAFLD spectrum is urgently needed. Phellinus igniarius polysaccharides (PIPs) are the most important bioactive components of P. igniarius (PI), exhibiting a variety of beneficial biological activities. However, their potential role in preventing NAFLD and the underlying mechanisms remain unclear. In this study, we revealed that PIPs reduced lipid deposition and injury in hepatocytes. PIPs ameliorate liver lipid deposition, inflammation, and fibrosis in mice fed a high‐fat diet (HFD). Mechanistically, RNA‐seq analysis indicated that lipid metabolism‐related signaling pathways were significantly enriched following PIP treatment. We further identified that PIP treatment inhibited sterol regulatory element‐binding protein 1 (SREBP1), reduced the expression of the downstream fat synthesis‐related genes fatty acid synthase (FASN) and stearoyl‐CoA desaturase (SCD1), and hence alleviated liver fat accumulation and body fat storage. Monosaccharide composition analysis and molecular docking of PIPs revealed that glucuronic acid, a main component of PIPs, inhibited lipid deposition in hepatocytes by binding to SREBP1. In summary, our current study reveals a new function of PIPs in the suppression of lipid synthesis and provides a new strategy for the prevention and treatment of NAFLD.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: